Welcome to our dedicated page for Neuropace SEC filings (Ticker: NPCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
Geiger Uri reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Uri Geiger received 913 shares of Common Stock as a grant on March 20, 2026 at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. Following the grant, he holds 14,858 shares directly and an additional 4,432,948 shares indirectly through Accelmed Partners II LP, where he has sole voting and dispositive power over the held shares.
LACOB JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Joseph Lacob received a grant of 865 shares of common stock at $13.00 per share as part of non-employee director compensation in lieu of quarterly retainer fees. Following this award, he holds 14,754 shares directly, plus indirect holdings through Lacob Ventures LLC and LCT18 Investments.
Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Rakhi Kumar received an equity grant of 1,153 shares of Common Stock at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, bringing Kumar’s direct holdings to 19,160 shares.
Fischer Frank M reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Frank M. Fischer received 1,826 shares of Common Stock as a grant at $13.00 per share. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees.
Following this stock compensation, Fischer directly owns 595,177 shares, indicating this was a routine, compensation-related equity award rather than an open-market purchase or sale.
NeuroPace Inc’s chief medical officer Martha Morrell reported two recent stock transactions. On December 15, 2025, she completed an open-market sale of 25,000 shares of common stock at a weighted average price of $15.97 per share under a Rule 10b5-1 trading plan.
On March 3, 2026, 1,340 shares of common stock were withheld to cover tax obligations tied to the vesting of a restricted stock unit award, at a price of $13.83 per share. After these transactions, she directly held 48,624 shares of NeuroPace common stock.
NeuroPace Inc’s CEO Joel Becker reported a tax-related share withholding. On March 3, 2026, 5,023 shares of common stock were disposed of at $13.83 per share to satisfy tax withholding obligations tied to a restricted stock unit vesting. After this withholding, Becker directly owns 96,937 shares of NeuroPace common stock.
NeuroPace, Inc. (NPCE) files its annual report describing a focused neuromodulation business built around the RNS System, a brain-responsive implant that monitors electrical activity and delivers targeted stimulation to prevent seizures in adults with drug‑resistant focal epilepsy.
The company highlights extensive clinical data showing long‑term seizure reduction, quality‑of‑life gains and a favorable safety profile versus resective surgery and other neuromodulation devices. As of December 31, 2025, over 8,000 patients had received the RNS System, supporting a U.S. target market of about 575,000 adults with drug‑resistant focal epilepsy and a broader 1.2 million drug‑resistant epilepsy population.
NeuroPace is pursuing growth by deepening penetration in Level 4 epilepsy centers, expanding into community practices, seeking FDA label expansions into idiopathic generalized epilepsy and pediatric patients, and selectively entering international markets. In February 2025 it raised approximately $69.7 million in net equity proceeds, using $49.5 million to repurchase shares from major stockholder KCK Ltd. and reserving the balance for general corporate purposes.
NeuroPace, Inc. reported strong growth for Q4 and full year 2025 while narrowing losses and laying out 2026 guidance. Q4 2025 revenue rose 24% to $26.6 million, driven mainly by RNS System sales of $22.4 million (up 26% year over year). Total gross margin improved to 77.4%, and RNS gross margin reached 80.5%, helping cut Q4 net loss to $2.7 million from $5.3 million a year earlier.
For 2025, revenue increased 25% to $100.0 million, with RNS System revenue of $81.7 million also up 25%. Full‑year gross margin expanded to 77.2%, and Adjusted EBITDA improved to a loss of $5.0 million. Cash, cash equivalents and short‑term investments were $61.1 million at December 31, 2025, with long‑term debt of $58.9 million.
The company plans to report DIXI Medical as discontinued operations starting in Q1 2026 and issued 2026 guidance on a continuing‑operations basis. It targets $98–$100 million in 2026 revenue, reflecting 20–22% RNS growth, non‑GAAP gross margin of 81.5–82.5%, non‑GAAP operating expenses of $90–$92 million, and Adjusted EBITDA between ($9.0) and ($10.0) million.
NeuroPace CEO Joel Becker reported a tax-related share withholding tied to a restricted stock unit vesting. On February 27, 2026, 1,126 shares of common stock were withheld by the company at $14.58 per share to cover tax obligations. After this tax-withholding disposition, Becker directly owned 101,960 shares.
NeuroPace Inc's chief medical officer reports a small share disposition tied to tax withholding. On February 27, 2026, 358 shares of common stock were withheld at $14.58 per share to satisfy tax obligations from a restricted stock unit vesting, rather than an open-market sale. Following this tax-withholding disposition, Martha Morrell directly held 74,964 shares of NeuroPace common stock.